Evolution of melanoma cross-resistance to CD8(+) T cells and MAPK inhibition in the course of BRAFi treatment

The profound but frequently transient clinical responses to BRAF(V600) inhibitor (BRAFi) treatment in melanoma emphasize the need for combinatorial therapies. Multiple clinical trials combining BRAFi and immunotherapy are under way to further enhance therapeutic responses. However, to which extent B...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Oncoimmunology
Egile Nagusiak: Pieper, Natalia, Zaremba, Anne, Leonardelli, Sonia, Harbers, Franziska Noelle, Schwamborn, Marion, Lübcke, Silke, Schrörs, Barbara, Baingo, Jolanthe, Schramm, Alexander, Haferkamp, Sebastian, Seifert, Ulrike, Sucker, Antje, Lennerz, Volker, Wölfel, Thomas, Schadendorf, Dirk, Schilling, Bastian, Paschen, Annette, Zhao, Fang
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Taylor & Francis 2018
Gaiak:
Original Research
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6136878/
https://ncbi.nlm.nih.gov/pubmed/30221038
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2018.1450127
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak